Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cp-724714. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-724714 SCHEMBL4617807 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL95109 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL30450143 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL4796165 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6169707 | 0.99 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6169715 | 0.99 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168343 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168355 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168480 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168463 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024200612-A1 | INHIBITORS OF URIDINE CATABOLISM AND/OR TRANSPORT FOR THERAPY | Université de Lausanne (CH) | 2024-10-03 | — | — | WO | claimed |
| EP-4705302-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705301-A2 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4705300-A1 | PYRIDO[4,3-D]PYRIMIDINE DERIVATIVES AS MUTANT KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER | Frontier Medicines Corporation (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025261943-A1 | ANTI-CANCER COMBINATIONS COMPRISING MOSPERAFENIB AND FOLFOX OR FOLFIRI | F. HOFFMANN-LA ROCHE AG (CH) | 2025-12-26 | — | — | WO | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| EP-4634172-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | F. Hoffmann-La Roche AG (CH) | 2025-10-22 | — | — | EP | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-112955137-B | Combination therapy | 米拉蒂治疗股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-117813094-A | Combinations of specific BRAF inhibitors (paradox inhibitors) and PD-1 axis binding antagonists for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024006445-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023150394-A1 | METHODS FOR TREATMENT OF CANCER | FRONTIER MEDICINES CORPORATION (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023078881-A1 | NOVEL USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081840-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4161907-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINON COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array BioPharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022258612-A1 | COMBINATION THERAPY FOR CANCER TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258600-A1 | COMBINATION OF A PARTICULAR BRAF INHIBITOR (PARADOX BREAKER) AND A PD-1 AXIS BINDING ANTAGONIST FOR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-12-15 | — | — | WO | disclosed |
| EP-3990437-A1 | QUINAZOLIN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | Array Biopharma, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |